李奕德醫師
引用



主治專長
1. 糖尿病
2. 甲狀腺疾病
3. 其他內分疾病
2. 甲狀腺疾病
3. 其他內分疾病
專業經驗
曾任臺中榮民總醫院內分泌暨新陳代謝科主任
重要經歷/進修訓練
美國加州 Cedars-Sinai Medical Center 研究員
曾任中華民國糖尿病學會副秘書長
曾任中華民國糖尿病衛教學會理事
曾任中華民國糖尿病學會副秘書長
曾任中華民國糖尿病衛教學會理事
學歷
國立陽明大學醫學系畢業
中山醫學大學醫學研究所碩士
中山醫學大學醫學研究所博士
中山醫學大學醫學研究所碩士
中山醫學大學醫學研究所博士
專科證照
中華民國內科醫學會會員
中華民國內分泌醫學會會員
中華民國糖尿病學會會員
中華民國糖尿病衛教學會會員
中華民國骨質疏鬆症學會專科醫師
中華民國內分泌醫學會會員
中華民國糖尿病學會會員
中華民國糖尿病衛教學會會員
中華民國骨質疏鬆症學會專科醫師
教師資格
教育部部定教授
陽明大學醫學系兼任教授
陽明大學醫學系兼任教授
研究興趣
肥胖與減重
糖尿病與心血管疾病
糖尿病與腎臟疾病
甲狀腺功能與壓力
糖尿病與心血管疾病
糖尿病與腎臟疾病
甲狀腺功能與壓力
進行中之計劃
國家衛生研究院整合性醫藥衛生科技研究計畫- 運用人工智慧整合基礎與臨床資訊建構糖尿病及各式併發症精準醫療
代表作
1. Li YH, Sheu WH, Lee IT* (2020, Oct). Use of the ankle-brachial index combined with the percentage of mean arterial pressure at the ankle to improve prediction of all-cause mortality in type 2 diabetes mellitus: an observational study. Cardiovasc Diabetol, 19(1),173. [利用踝臂動脈壓比值與踝部平均動脈壓百分比改善預測第二型糖尿病患者的總死亡率: 觀察性研究]
2. Li YH, Lee IT* (2020, Oct). Hyperthyroidism and vascular cell adhesion molecule-1 are associated with a low ankle-brachial index. Sci Rep, 10(1), 17076. [甲狀腺亢進與血管细胞黏附分子-1與踝臂動脈壓比值相關]
3. Lee IT, Li YH, Sheu WH (2020, Jul). Brain-Derived Neurotrophic Factor during Oral Glucose Tolerance Test Predicts Cardiovascular Outcomes. Int J Mol Sci, 21(14), 5008. [口服葡萄糖試驗後的腦源神經滋養因子可預測心血管的預後]
4. Lee IT*. (2020, Mar). Mean and variability of annual haemoglobin A1c are associated with high-risk peripheral artery disease.. Diabetes & Vascular Disease Research, 17(3),1479164120909030. [年度糖化血色素的平均值與波動性與高風險周邊血管相關]
5. Cheng YC, Li YH, Hsu CY, Lee IT* (2020, Jun). Synergistic Association of Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 on the Risk of Abnormal Glucose Regulation. Diabetes Metab Syndr Obes, 13,1933-1942.
6. Pai YW, Tang CL, Lin CH, Lin SY, Lee IT*, Chang MH. (2020, May). Glycaemic control for painful diabetic peripheral neuropathy is more than fasting plasma glucose and glycated haemoglobin. Diabetes & Metabolism, S1262-3636(20),
7. Li YH, Sheu WH, Lee IT*. (2020, Mar). Influence of Diabetic Retinopathy on the Relationship Between Body Mass Index and Mortality in Patients with Poorly Controlled Type 2 Diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13,907-914. MOST 108-2314-B-075A-002.
8. Liao CC, Sheu WH, Lin SY, Lee WJ, Lee IT*. (2020, Jan). The Relationship Between Abdominal Body Composition and Metabolic Syndrome After a Weight Reduction Program in Adult Men with Obesity. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13,1-8.
註: *代表本人為通訊作者.
2. Li YH, Lee IT* (2020, Oct). Hyperthyroidism and vascular cell adhesion molecule-1 are associated with a low ankle-brachial index. Sci Rep, 10(1), 17076. [甲狀腺亢進與血管细胞黏附分子-1與踝臂動脈壓比值相關]
3. Lee IT, Li YH, Sheu WH (2020, Jul). Brain-Derived Neurotrophic Factor during Oral Glucose Tolerance Test Predicts Cardiovascular Outcomes. Int J Mol Sci, 21(14), 5008. [口服葡萄糖試驗後的腦源神經滋養因子可預測心血管的預後]
4. Lee IT*. (2020, Mar). Mean and variability of annual haemoglobin A1c are associated with high-risk peripheral artery disease.. Diabetes & Vascular Disease Research, 17(3),1479164120909030. [年度糖化血色素的平均值與波動性與高風險周邊血管相關]
5. Cheng YC, Li YH, Hsu CY, Lee IT* (2020, Jun). Synergistic Association of Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 on the Risk of Abnormal Glucose Regulation. Diabetes Metab Syndr Obes, 13,1933-1942.
6. Pai YW, Tang CL, Lin CH, Lin SY, Lee IT*, Chang MH. (2020, May). Glycaemic control for painful diabetic peripheral neuropathy is more than fasting plasma glucose and glycated haemoglobin. Diabetes & Metabolism, S1262-3636(20),
7. Li YH, Sheu WH, Lee IT*. (2020, Mar). Influence of Diabetic Retinopathy on the Relationship Between Body Mass Index and Mortality in Patients with Poorly Controlled Type 2 Diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13,907-914. MOST 108-2314-B-075A-002.
8. Liao CC, Sheu WH, Lin SY, Lee WJ, Lee IT*. (2020, Jan). The Relationship Between Abdominal Body Composition and Metabolic Syndrome After a Weight Reduction Program in Adult Men with Obesity. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13,1-8.
註: *代表本人為通訊作者.